Early drug use of dapagliflozin prescribed by general practitioners and diabetologists in Germany-Reference-Cited by-同舟云学术

Early drug use of dapagliflozin prescribed by general practitioners and diabetologists in Germany

Published:2017-03 Issue: Volume:125 Page:29-38
ISSN:0168-8227
Container-title:Diabetes Research and Clinical Practice
language:en
Short-container-title:Diabetes Research and Clinical Practice

Author:

Hankins Matthew,Tsai Katherine,Kim Joseph,Hammar Niklas

Publisher

Elsevier BV

Subject

Endocrinology,General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference22 articles.

1. IDF diabetes atlas sixth edition [Internet]. International Diabetes Federation. 2014. Ref Type: Online Source.

2. Diabetes Mellitus in German Primary Care: quality of glycaemic control and subpopulations not well controlled results of the DETECT study;Huppertz;Exp Clin Endocrinol Diabetes,2009

3. Summary of Product Characteristics: Forxiga 5 mg & 10 mg film coated tablets [Internet]. emc. 2014. Ref Type: Internet Communication.

4. European Medicines Agency. Assessment Report: Forxiga (dapagliflozin). 18 September 2012. EMA/689976/2012. Committee for Medicinal Products for Human Use (CHMP). 2012. Ref Type: Internet Communication.

5. The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP). Guide on Methodological Standards in Pharmacoepidemiology (Revision 2). EMA/95098/2010. 2014. Ref Type: Internet Communication.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Promising renoprotective effect of gold nanoparticles and dapagliflozin in diabetic nephropathy via targeting miR‐192 and miR‐21;Journal of Biochemical and Molecular Toxicology;2023-06-23

2. Kinetics of Dapagliflozin after single dose oral administration of a 10 mg immediate release tablet;Studia Universitatis Babeș-Bolyai Chemia;2019-06-30

3. Empagliflozin-induced Diabetic Ketoacidosis Unmasking a Type 1 Diabetes Diagnosis;Clinical Practice and Cases in Emergency Medicine;2019-03-05

4. Characteristics of Patients with Diabetes Initiating Sodium Glucose Co-transporter-2 Inhibitors (SGLT2i): Real-World Results from Three Administrative Databases in Japan;Diabetes Therapy;2019-02-07

5. Rationale and design of the DARWIN-T2D (DApagliflozin Real World evIdeNce in Type 2 Diabetes);Nutrition, Metabolism and Cardiovascular Diseases;2017-12